BMY
Bristol-Myers Squibb Company · NYSE · Healthcare · USD · 10-K for 2025, filed 2026-02-11
Figures on this page computed 2026-11-08 12:24 UTC
Last close
62.14USD
Market data, 2026-11-06
Except where said otherwise: 10-K for 2025, filed 2026-02-11
17.9xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0000014272-26-000004
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-11
15.3%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0000014272-26-000004
- Reported in
- USD
- 10-K for 2025, filed 2026-02-11
- 10-K for 2025, filed 2026-02-11
- 10-K for 2025, filed 2026-02-11
- 10-Q for 2025, filed 2026-10-29
- 10-K for 2025, filed 2026-02-11
- 10-Q for 2025, filed 2026-10-29
14.6%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0000014272-26-000004
- Reported in
- USD
- 10-K for 2025, filed 2026-02-11
- 10-K for 2025, filed 2026-02-11
26.6%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0000014272-26-000004
- Reported in
- USD
- 10-K for 2025, filed 2026-02-11
- 10-K for 2025, filed 2026-02-11
2.55Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0000014272-26-000004
- Reported in
- USD
- 10-K for 2025, filed 2026-02-11
- 10-Q for 2025, filed 2026-10-29
4.1%Dividend yield
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
- computed
- computed
- computed
- computed
- Computed from the filing for 2025, filed 2026-02-11
Safety is the furthest below its sector's middle: 0.21 against 0.71 on the market's range.
Against its rival
lens 4 of 9Measure by measure
behind on 4 of 4- Profit on each unit of sales14.6%17.5%Behind
Higher is better here.
- Return on the capital it uses15.3%n/an/a
Higher is better here.
- Sales growth over five years2.5%6.1%Behind
Higher is better here.
- Debt against equity2.55n/an/a
Lower is better here.
- Gross margin71.1%72.4%Behind
Higher is better here.
- Price against earnings17.9x13.3xBehind
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against GSK plc, BMY is behind on 4 of 4 measures.
Against GSK plc, BMY is behind on 4 of 4 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-11
Profit on each unit of sales14.6%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0000014272-26-000004
- Reported in
- USD
Return on the capital it uses15.3%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0000014272-26-000004
- Reported in
- USD
Sales growth over five years2.5%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0000014272-26-000004
- Reported in
- USD
Debt against equity2.55
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0000014272-26-000004
- Reported in
- USD
Gross margin71.1%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0000014272-26-000004
- Reported in
- USD
Price against earnings17.9x
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0000014272-26-000004
- Reported in
- USD